ATE87825T1 - Zusammensetzungen essentieller fettsaeuren. - Google Patents

Zusammensetzungen essentieller fettsaeuren.

Info

Publication number
ATE87825T1
ATE87825T1 AT89305345T AT89305345T ATE87825T1 AT E87825 T1 ATE87825 T1 AT E87825T1 AT 89305345 T AT89305345 T AT 89305345T AT 89305345 T AT89305345 T AT 89305345T AT E87825 T1 ATE87825 T1 AT E87825T1
Authority
AT
Austria
Prior art keywords
essential fatty
compositions
fatty acids
fatty acid
acid selected
Prior art date
Application number
AT89305345T
Other languages
English (en)
Inventor
David Frederick Horrobin
Meadows Woodbridge
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE87825T1 publication Critical patent/ATE87825T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT89305345T 1988-06-10 1989-05-26 Zusammensetzungen essentieller fettsaeuren. ATE87825T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888813766A GB8813766D0 (en) 1988-06-10 1988-06-10 Essential fatty acid compositions
EP89305345A EP0347056B1 (de) 1988-06-10 1989-05-26 Zusammensetzungen essentieller Fettsäuren

Publications (1)

Publication Number Publication Date
ATE87825T1 true ATE87825T1 (de) 1993-04-15

Family

ID=10638418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89305345T ATE87825T1 (de) 1988-06-10 1989-05-26 Zusammensetzungen essentieller fettsaeuren.

Country Status (13)

Country Link
US (2) US4977187A (de)
EP (2) EP0347056B1 (de)
JP (1) JP2796838B2 (de)
KR (1) KR0129666B1 (de)
AT (1) ATE87825T1 (de)
AU (2) AU618814B2 (de)
CA (1) CA1334004C (de)
DE (1) DE68905863T2 (de)
ES (1) ES2053990T3 (de)
GB (1) GB8813766D0 (de)
IE (1) IE63303B1 (de)
NZ (1) NZ229423A (de)
ZA (1) ZA894380B (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US6103755A (en) * 1990-05-22 2000-08-15 Bumann; Harold Foodstuff with prophylactic and/or healing effect and process for its production
DE69004081T2 (de) * 1990-05-23 1994-02-10 Nestle Sa Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
FR2679109B1 (fr) * 1991-07-18 1994-03-11 Institut Recherche Biologique Sa Nouveaux complements nutritionnels ou dietetiques anti-vieillissement a base d'acide gras poly-insature.
JPH07114761B2 (ja) * 1991-08-29 1995-12-13 ジェクス株式会社 皮膚清拭用品
US5436269A (en) * 1991-11-14 1995-07-25 Sagami Chemical Research Center Method for treating hepatitis
EP0614359A1 (de) * 1991-11-26 1994-09-14 Warner-Lambert Company Wundheilende zusammensetzungen die ein pyruvat, ein antioxidant und eine fettsaeuremischung enthalten
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
JPH08511533A (ja) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
EP0734723A4 (de) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd Therapeutisches präparat zur behandlung von hyperparathyroidismus bei dialysepatienten
DE69513172T2 (de) * 1994-06-22 2000-08-24 Asahi Kasei Kogyo K.K., Osaka Verfahren zur herstellung von methacrolein
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
DE69724629T2 (de) * 1996-06-03 2004-07-29 Croda International Plc., Goole Zusammensetzungen und deren verwendungen
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
ES2195175T3 (es) * 1996-10-11 2003-12-01 Scarista Ltd Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
GB9724783D0 (en) 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7138431B1 (en) * 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
EP1423107B1 (de) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fettalkohol-arzneimittel-konjugate
AU2002318135B2 (en) * 2001-05-14 2007-08-02 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
WO2002092540A1 (en) * 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms
EP1285590A1 (de) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipidmischungen
EP1450787A4 (de) * 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc Formulierungen und verfahren zur behandlung oder linderung von entzündlichen zuständen
FR2833174B1 (fr) * 2001-12-06 2004-05-28 Margaret Bronnert Pommade grasse d'origine animale destinee a soulager des demangeaisons et irritations de la peau dues aux dermites, eczema atopique et psoriasis,secheresse cutanee et hyperkeratinose
US7163960B2 (en) 2002-03-08 2007-01-16 Monsanto Technology L.L.C. Treatment and prevention of inflammatory disorders
AU2003247685A1 (en) * 2002-07-02 2004-01-23 Galileo Pharmaceuticals, Inc. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004012753A1 (en) * 2002-07-31 2004-02-12 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
PL1656449T3 (pl) 2003-08-21 2009-08-31 Monsanto Technology Llc Desaturazy kwasów tłuszczowych z Primula
WO2005063231A2 (en) * 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
JP2007524674A (ja) * 2004-01-19 2007-08-30 マーテック・バイオサイエンシーズ・コーポレーション リーリン欠損症または機能障害およびそれに関連する方法
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
HRP20060326A2 (hr) * 2004-03-12 2007-02-28 Egis Gy�gyszergy�r Nyrt. Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
CA2562548C (en) 2004-04-16 2019-08-20 Monsanto Technology Llc Expression of fatty acid desaturases in corn
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물
ATE469957T1 (de) 2004-11-04 2010-06-15 Monsanto Technology Llc Verfahren zur herstellung von ölzusammensetzungen
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
BR122018075948B1 (pt) 2006-03-10 2023-05-16 Monsanto Technology Llc Métodos de produzir uma planta de soja com teor de ácidos graxos de semente alterados
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
AU2008361645A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9480271B2 (en) 2009-09-15 2016-11-01 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
EP2708230B1 (de) 2011-05-12 2024-10-02 Nissui Corporation Zusammensetzung zur äusserlichen anwendung auf der haut für entzündliche erkrankungen
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
CN114410374B (zh) 2013-12-04 2025-01-07 株式会社日水 微生物油、微生物油的制造方法、浓缩微生物油及浓缩微生物油的制造方法
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
AU2022328181A1 (en) 2021-08-09 2024-03-21 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) * 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Also Published As

Publication number Publication date
AU618814B2 (en) 1992-01-09
DE68905863T2 (de) 1993-08-26
NZ229423A (en) 1992-10-28
CA1334004C (en) 1995-01-17
AU7943491A (en) 1991-09-12
ES2053990T3 (es) 1994-08-01
KR0129666B1 (ko) 1998-04-09
ZA894380B (en) 1990-02-28
EP0454102A3 (en) 1992-01-02
IE891819L (en) 1989-12-10
JP2796838B2 (ja) 1998-09-10
US5120760A (en) 1992-06-09
JPH0232017A (ja) 1990-02-01
EP0454102A2 (de) 1991-10-30
KR900000078A (ko) 1990-01-30
EP0347056A1 (de) 1989-12-20
IE63303B1 (en) 1995-04-05
US4977187A (en) 1990-12-11
EP0347056B1 (de) 1993-04-07
AU3597489A (en) 1989-12-14
DE68905863D1 (de) 1993-05-13
GB8813766D0 (en) 1988-07-13
AU633442B2 (en) 1993-01-28

Similar Documents

Publication Publication Date Title
DE68905863D1 (de) Zusammensetzungen essentieller fettsaeuren.
PT956013E (pt) Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico
NO940277L (no) Triglycerider og blandinger av slike
ES2060290T3 (es) Composiciones de acidos grasos esenciales (efa) y terapia.
AU586892B2 (en) Pharmaceutical and dietary composition
EP0440307A3 (de) Pharmazeutische und diätetische Zusammensetzung
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
TW336171B (en) Pharmaceutical composition for use in the treatment of vulvar dystrophy and/or vaginal dryness
DE60008127D1 (de) Diät mit hohem lipidgehalt
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
IE842424L (en) Topical preparations containing tar and fatty acids
MX9207150A (es) Metodo y composiciones para reducir la resistenciaa multiples farmacos.
BR9705425A (pt) Preparações pulverulentas dispersíveis em água.
ATE24111T1 (de) Mischung mit gehalt an einem zentral-analgetikum und an vitamine b12 oder einem seiner analoge als wirkstoffe.
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
IT8722398A0 (it) Composizioni dietetiche in particolare per condizioni di accresciuto catabolismo proteico.
DE59609482D1 (de) Anellierte beta-carboline
TH15810A (th) สูตรผสมที่มีกรดแฟททีชนิดไม่อิ่มตัว

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee